Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Human TNFSF15 Antikörper:
anti-Mouse (Murine) TNFSF15 Antikörper:
anti-Rat (Rattus) TNFSF15 Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Polyclonal TNFSF15 Primary Antibody für WB - ABIN2476844
Tinkanen, Kujansuu: Doppler ultrasound studies in pelvic inflammatory disease. in Gynecologic and obstetric investigation 1993
Show all 3 Pubmed References
Human Polyclonal TNFSF15 Primary Antibody für IF (p), IHC (p) - ABIN709556
?lebioda, Bojarska-Junak, Stanis?awowski, Cyman, Wierzbicki, Roli?ski, Celi?ski, Kmie?: TL1A as a potential local inducer of IL17A Expression in colon mucosa of inflammatory bowel disease patients. in Scandinavian journal of immunology 2015
TL1A modulated Rheumatoid arthritis-fibroblast-like synoviocytes migration and Indian hedgehog (zeige IHH Antikörper) signaling pathway using TNFR2 (zeige TNFRSF1B Antikörper).
TL1A can induce tumor cell proliferation and promote the occurrence of colitis-associated colorectal cancer by activating Wnt (zeige WNT2 Antikörper)/beta-catenin (zeige CTNNB1 Antikörper) pathway.
TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC (zeige VEGFC Antikörper) expression in A549 cells.
Results suggested that TNFSF15 (rs3810936 and rs4979462) SNPs may confer susceptibility to systemic lupus erythematosus (SLE) risk, which were significantly associated with the clinical phenotypes of SLE.
Three alternatively spliced isoforms of VEGI, VEGI174, VEGI192 and VEGI251 have been documented. This study investigated the effects of VEGI174 and its functional domains (V7 and V8) on epithelialmesenchymal transition (EMT (zeige ITK Antikörper)) in renal cell carcinoma (zeige MOK Antikörper) (RCC (zeige XRCC1 Antikörper)) cells in vitro. Overexpression of VEGI174, V7 or V8 inhibited EMT (zeige ITK Antikörper).
Results provide evidence that variance within TNFSF15 has the potential to affect cytokine expression across a range of tissues and thereby contribute to protection from infectious diseases such as leprosy, while increasing the risk of immune-mediated diseases including Crohn's disease and primary biliary cholangitis.
single variant analysis detected a previously unreported psoriasis risk locus at TNFSF15 (rs6478108)
the DR3 (zeige TNFRSF25 Antikörper)/TL1A pathway directly enhances human OC formation and resorptive activity, controlling expression and activation of CCL3 (zeige CCL3 Antikörper) and MMP-9 (zeige MMP9 Antikörper).
the blocking of tumor necrosis factor receptor 2 (TNFR2 (zeige TNFRSF1B Antikörper)) decreased TL1A-stimulated IL-6 (zeige IL6 Antikörper) production by rheumatoid arthritis fibroblast-like synoviocytes.
Distinct but overlapping TNFSF15 haplotypes were demonstrated in diverticulitis patients versus healthy controls when compared with the known Crohn's risk haplotype suggesting similar but distinct genetic predispositions. This study strengthens the role for a genetic predisposition to diverticulitis that involves the TNFSF15 gene.
TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis
ATF3 (zeige ATF3 Antikörper) protects against LPS (zeige TLR4 Antikörper)-induced acute lung injury by inhibiting TL1A expression.
This work describes both a novel function and essential requirement for the DR3 (zeige TNFRSF25 Antikörper)/TL1A pathway in acute, resolving, and chronic inflammation in the peritoneal cavity.
this study shows that TL1A-/- mice are more susceptible to dextran sodium sulfate colitis
These data demonstrated a direct role for TL1A-DR3 (zeige TNFRSF25 Antikörper) signaling in tissue fibrosis and that modulation of TL1A-DR3 (zeige TNFRSF25 Antikörper) signaling could inhibit gut (zeige GUSB Antikörper) fibrosis.
these data identify TL1A-DR3 (zeige TNFRSF25 Antikörper) interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9 (zeige IL9 Antikörper).
TL1A induces NF-kappaB (zeige NFKB1 Antikörper) activation in EC in renal and cardiac tissue from wild type but not DR3 (zeige TNFRSF25 Antikörper) knock-out mice.
TL1A deficiency impacts on the gut (zeige GUSB Antikörper) microbial composition and the mucosal immune system, especially the intraepithelial TCRgammadelta(+) T-cell subset, and that TL1A is involved in the establishment of adipose tissue.
Our data demonstrate a key role for TL1A in promoting ILC2s at mucosal barriers.
TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor (zeige FLT1 Antikörper) 1.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Two transcript variants encoding different isoforms have been found for this gene.
tumor necrosis factor ligand superfamily member 15
, vascular endothelial growth inhibitor
, tocopherol (alpha) transfer protein-like
, TNF ligand-related molecule 1
, TNF superfamily ligand TL1A
, vascular endothelial cell growth inhibitor
, vascular endothelial growth inhibitor-192A
, bM20K13.3 (tumor necrosis factor (ligand) superfamily, member 15)